Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

Development of a nasal spray containing xylometazoline hydrochloride and iota-carrageenan for the symptomatic relief of nasal congestion caused by rhinitis and sinusitis.

Graf C, Bernkop-Schnürch A, Egyed A, Koller C, Prieschl-Grassauer E, Morokutti-Kurz M.

Int J Gen Med. 2018 Jul 4;11:275-283. doi: 10.2147/IJGM.S167123. eCollection 2018.

2.

Object discrepancy modulates feature prediction across eye movements.

Köller CP, Poth CH, Herwig A.

Psychol Res. 2018 Jan 31. doi: 10.1007/s00426-018-0988-5. [Epub ahead of print]

PMID:
29387939
3.

Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6.

Golob-Schwarzl N, Schweiger C, Koller C, Krassnig S, Gogg-Kamerer M, Gantenbein N, Toeglhofer AM, Wodlej C, Bergler H, Pertschy B, Uranitsch S, Holter M, El-Heliebi A, Fuchs J, Punschart A, Stiegler P, Keil M, Hoffmann J, Henderson D, Lehrach H, Reinhard C, Regenbrecht C, Schicho R, Fickert P, Lax S, Haybaeck J.

Oncotarget. 2017 Sep 5;8(60):101224-101243. doi: 10.18632/oncotarget.20642. eCollection 2017 Nov 24.

4.

Primary Care Spending Rate - A Lever for Encouraging Investment in Primary Care.

Koller CF, Khullar D.

N Engl J Med. 2017 Nov 2;377(18):1709-1711. doi: 10.1056/NEJMp1709538. No abstract available.

5.

Comparison of Two Sources of Clinical Audit Data to Assess the Delivery of Diabetes Care in Aboriginal Communities.

Regan T, Paul C, Ishiguchi P, D'Este C, Koller C, Forshaw K, Noble N, Oldmeadow C, Bisquera A, Eades S.

Int J Environ Res Public Health. 2017 Oct 17;14(10). pii: E1236. doi: 10.3390/ijerph14101236.

6.

Testing for type 2 diabetes in Indigenous Australians: guideline recommendations and current practice.

Paul CL, Ishiguchi P, D'Este CA, Shaw JE, Sanson-Fisher RW, Forshaw K, Bisquera A, Robinson J, Koller C, Eades SJ.

Med J Aust. 2017 Aug 4;207(5):206-210.

PMID:
28987134
7.

A Way Forward for Bipartisan Health Reform? Democrat and Republican State Legislator Priorities for the Goals of Health Policy.

Pagel C, Bates DW, Goldmann D, Koller CF.

Am J Public Health. 2017 Oct;107(10):1601-1603. doi: 10.2105/AJPH.2017.304023. Epub 2017 Aug 17. No abstract available.

8.

Precision of guided scanning procedures for full-arch digital impressions in vivo.

Zimmermann M, Koller C, Rumetsch M, Ender A, Mehl A.

J Orofac Orthop. 2017 Nov;78(6):466-471. doi: 10.1007/s00056-017-0103-3. Epub 2017 Jul 21.

PMID:
28733810
9.

Clinical Evaluation of Indirect Particle-Filled Composite Resin CAD/CAM Partial Crowns after 24 Months.

Zimmermann M, Koller C, Reymus M, Mehl A, Hickel R.

J Prosthodont. 2017 Apr 19. doi: 10.1111/jopr.12582. [Epub ahead of print]

10.

Heterogeneity of systematic reviews in oncology.

Holmes J, Herrmann D, Koller C, Khan S, Umberham B, Worley JA, Vassar M.

Proc (Bayl Univ Med Cent). 2017 Apr;30(2):163-166. Review.

11.

Statistical controversies in clinical research: publication bias evaluations are not routinely conducted in clinical oncology systematic reviews.

Herrmann D, Sinnett P, Holmes J, Khan S, Koller C, Vassar M.

Ann Oncol. 2017 May 1;28(5):931-937. doi: 10.1093/annonc/mdw691. Review.

PMID:
28039176
12.

Population Health - A Bipartisan Agenda for the Incoming Administration from State Leaders.

Koller CF, Alexander T, Birch S.

N Engl J Med. 2017 Jan 19;376(3):200-202. doi: 10.1056/NEJMp1613250. Epub 2016 Dec 14. No abstract available.

13.

Indirect zirconia-reinforced lithium silicate ceramic CAD/CAM restorations: Preliminary clinical results after 12 months.

Zimmermann M, Koller C, Mehl A, Hickel R.

Quintessence Int. 2017;48(1):19-25. doi: 10.3290/j.qi.a37017.

PMID:
27822572
14.

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.

Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umaña P, Mössner E.

Protein Eng Des Sel. 2016 Oct;29(10):457-466. doi: 10.1093/protein/gzw040. Epub 2016 Aug 29.

PMID:
27578889
15.

United's Withdrawal from Exchanges--Much Ado about the Wrong Things?

Koller CF.

N Engl J Med. 2016 Jul 28;375(4):303-5. doi: 10.1056/NEJMp1605841. Epub 2016 Jun 22. No abstract available.

PMID:
27331933
16.

Parameters Associated with Marginal Bone Loss around Implant after Prosthetic Loading.

Koller CD, Pereira-Cenci T, Boscato N.

Braz Dent J. 2016 May-Jun;27(3):292-7. doi: 10.1590/0103-6440201600874.

17.

Chairside treatment of amelogenesis imperfecta, including establishment of a new vertical dimension with resin nanoceramic and intraoral scanning.

Zimmermann M, Koller C, Hickel R, Kühnisch J.

J Prosthet Dent. 2016 Sep;116(3):309-13. doi: 10.1016/j.prosdent.2016.02.010. Epub 2016 Apr 23.

PMID:
27112411
18.

How can we improve stroke thrombolysis rates? A review of health system factors and approaches associated with thrombolysis administration rates in acute stroke care.

Paul CL, Ryan A, Rose S, Attia JR, Kerr E, Koller C, Levi CR.

Implement Sci. 2016 Apr 8;11:51. doi: 10.1186/s13012-016-0414-6. Review.

19.

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P.

Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1.

20.

Transparency and the Supreme Court--Can Employers Refuse to Disclose How Much They Pay for Health Care?

Bagley N, Koller C.

N Engl J Med. 2015 Dec 31;373(27):e34. doi: 10.1056/NEJMp1513895. Epub 2015 Nov 25. No abstract available.

PMID:
26605801
21.

Experiences of using a commercial dose management system (GE DoseWatch) for CT examinations.

Nicol RM, Wayte SC, Bridges AJ, Koller CJ.

Br J Radiol. 2016;89(1057):20150617. doi: 10.1259/bjr.20150617. Epub 2015 Nov 5.

PMID:
26539632
22.

Database choices in endocrine systematic reviews.

Vassar M, Carr B, Kash-Holley M, DeWitt E, Koller C, Day J, Day K, Herrmann D, Holzmann M.

J Med Libr Assoc. 2015 Oct;103(4):189-92. doi: 10.3163/1536-5050.103.4.005.

23.
24.

State Leadership in Health Care Transformation: Red and Blue.

Hwang A, Sharfstein JM, Koller CF.

JAMA. 2015 Jul 28;314(4):349-50. doi: 10.1001/jama.2015.8211. No abstract available.

PMID:
26219050
25.

The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model.

Morokutti-Kurz M, König-Schuster M, Koller C, Graf C, Graf P, Kirchoff N, Reutterer B, Seifert JM, Unger H, Grassauer A, Prieschl-Grassauer E, Nakowitsch S.

PLoS One. 2015 Jun 8;10(6):e0128794. doi: 10.1371/journal.pone.0128794. eCollection 2015.

26.

Non-clinical safety evaluation of intranasal iota-carrageenan.

Hebar A, Koller C, Seifert JM, Chabicovsky M, Bodenteich A, Bernkop-Schnürch A, Grassauer A, Prieschl-Grassauer E.

PLoS One. 2015 Apr 13;10(4):e0122911. doi: 10.1371/journal.pone.0122911. eCollection 2015.

27.

Bi- to tetravalent glycoclusters presenting GlcNAc/GalNAc as inhibitors: from plant agglutinins to human macrophage galactose-type lectin (CD301) and galectins.

André S, O'Sullivan S, Koller C, Murphy PV, Gabius HJ.

Org Biomol Chem. 2015 Apr 14;13(14):4190-203. doi: 10.1039/c5ob00048c. Epub 2015 Feb 27.

PMID:
25721929
28.

Delineating binding modes of Gal/GalNAc and structural elements of the molecular recognition of tumor-associated mucin glycopeptides by the human macrophage galactose-type lectin.

Marcelo F, Garcia-Martin F, Matsushita T, Sardinha J, Coelho H, Oude-Vrielink A, Koller C, André S, Cabrita EJ, Gabius HJ, Nishimura S, Jiménez-Barbero J, Cañada FJ.

Chemistry. 2014 Dec 1;20(49):16147-55. doi: 10.1002/chem.201404566. Epub 2014 Oct 16.

PMID:
25324212
29.

Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.

Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K, Luthra R, Koller C, Brandt M, Ravandi F, Kantarjian H.

Am J Hematol. 2014 Oct;89(10):964-8. doi: 10.1002/ajh.23795. Epub 2014 Jul 21.

30.

Should occlusal splints be a routine prescription for diagnosed bruxers undergoing implant therapy?

Mesko ME, Almeida RC, Porto JA, Koller CD, da Rosa WL, Boscato N.

Int J Prosthodont. 2014 May-Jun;27(3):201-3. doi: 10.11607/ijp.3883. Review.

PMID:
24905259
31.

A global analysis of Y-chromosomal haplotype diversity for 23 STR loci.

Purps J, Siegert S, Willuweit S, Nagy M, Alves C, Salazar R, Angustia SM, Santos LH, Anslinger K, Bayer B, Ayub Q, Wei W, Xue Y, Tyler-Smith C, Bafalluy MB, Martínez-Jarreta B, Egyed B, Balitzki B, Tschumi S, Ballard D, Court DS, Barrantes X, Bäßler G, Wiest T, Berger B, Niederstätter H, Parson W, Davis C, Budowle B, Burri H, Borer U, Koller C, Carvalho EF, Domingues PM, Chamoun WT, Coble MD, Hill CR, Corach D, Caputo M, D'Amato ME, Davison S, Decorte R, Larmuseau MH, Ottoni C, Rickards O, Lu D, Jiang C, Dobosz T, Jonkisz A, Frank WE, Furac I, Gehrig C, Castella V, Grskovic B, Haas C, Wobst J, Hadzic G, Drobnic K, Honda K, Hou Y, Zhou D, Li Y, Hu S, Chen S, Immel UD, Lessig R, Jakovski Z, Ilievska T, Klann AE, García CC, de Knijff P, Kraaijenbrink T, Kondili A, Miniati P, Vouropoulou M, Kovacevic L, Marjanovic D, Lindner I, Mansour I, Al-Azem M, Andari AE, Marino M, Furfuro S, Locarno L, Martín P, Luque GM, Alonso A, Miranda LS, Moreira H, Mizuno N, Iwashima Y, Neto RS, Nogueira TL, Silva R, Nastainczyk-Wulf M, Edelmann J, Kohl M, Nie S, Wang X, Cheng B, Núñez C, Pancorbo MM, Olofsson JK, Morling N, Onofri V, Tagliabracci A, Pamjav H, Volgyi A, Barany G, Pawlowski R, Maciejewska A, Pelotti S, Pepinski W, Abreu-Glowacka M, Phillips C, Cárdenas J, Rey-Gonzalez D, Salas A, Brisighelli F, Capelli C, Toscanini U, Piccinini A, Piglionica M, Baldassarra SL, Ploski R, Konarzewska M, Jastrzebska E, Robino C, Sajantila A, Palo JU, Guevara E, Salvador J, Ungria MC, Rodriguez JJ, Schmidt U, Schlauderer N, Saukko P, Schneider PM, Sirker M, Shin KJ, Oh YN, Skitsa I, Ampati A, Smith TG, Calvit LS, Stenzl V, Capal T, Tillmar A, Nilsson H, Turrina S, De Leo D, Verzeletti A, Cortellini V, Wetton JH, Gwynne GM, Jobling MA, Whittle MR, Sumita DR, Wolańska-Nowak P, Yong RY, Krawczak M, Nothnagel M, Roewer L.

Forensic Sci Int Genet. 2014 Sep;12:12-23. doi: 10.1016/j.fsigen.2014.04.008. Epub 2014 Apr 28.

32.

Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.

O'Brien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR, Gersh BJ, Fonarow GC, Koller CR, Ezekowitz MD, Mahaffey KW, Chang P, Peterson ED, Piccini JP, Singer DE.

Am Heart J. 2014 Apr;167(4):601-609.e1. doi: 10.1016/j.ahj.2013.12.014. Epub 2014 Jan 4.

PMID:
24655711
33.

The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia.

Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M, Pierce S, Keating M, Cortes J, Kantarjian H, Ravandi F.

Front Oncol. 2013 Sep 6;3:218. doi: 10.3389/fonc.2013.00218. eCollection 2013.

34.

Influence of anxiety on temporomandibular disorders--an epidemiological survey with elders and adults in Southern Brazil.

Boscato N, Almeida RC, Koller CD, Presta AA, Goettems ML.

J Oral Rehabil. 2013 Sep;40(9):643-9. doi: 10.1111/joor.12076. Epub 2013 Jun 18.

PMID:
23782389
35.

Targeting renal cancer with a combination of WNT inhibitors and a bi-functional peptide.

Koller CM, Kim Y, Schmidt-Wolf IG.

Anticancer Res. 2013 Jun;33(6):2435-40.

PMID:
23749892
36.

Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.

Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F.

Br J Haematol. 2012 May;157(3):312-20. doi: 10.1111/j.1365-2141.2012.09064.x. Epub 2012 Feb 24.

37.

Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation.

Cornelison AM, Welch MA, Koller C, Jabbour E.

Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S111-3. doi: 10.1016/j.clml.2011.03.032. Epub 2011 Apr 28.

PMID:
22035739
38.

Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.

Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ.

J Clin Oncol. 2011 Nov 1;29(31):4088-95. doi: 10.1200/JCO.2010.33.9002. Epub 2011 Oct 3.

39.

Cavity QED with magnetically coupled collective spin states.

Amsüss R, Koller Ch, Nöbauer T, Putz S, Rotter S, Sandner K, Schneider S, Schramböck M, Steinhauser G, Ritsch H, Schmiedmayer J, Majer J.

Phys Rev Lett. 2011 Aug 5;107(6):060502. Epub 2011 Aug 3.

PMID:
21902306
40.

Communication: the key to effective interdisciplinary collaboration in the care of a child with complex rehabilitation needs.

Reber PA, DiPietro EA, Paraway Y, Obst BP, Smith RA, Koller CL.

Rehabil Nurs. 2011 Sep-Oct;36(5):181-5, 213.

PMID:
21882794
41.

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.

Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H.

Blood. 2011 Oct 6;118(14):3818-23. doi: 10.1182/blood-2011-04-351502. Epub 2011 Aug 5.

42.

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.

Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG.

Blood. 2011 Aug 25;118(8):2062-8. doi: 10.1182/blood-2011-01-329177. Epub 2011 Jul 12.

43.

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.

Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG.

Blood. 2011 Aug 25;118(8):2085-93. doi: 10.1182/blood-2011-03-341032. Epub 2011 Jun 13.

44.

Detection and function of an intramolecular disulfide bond in the pH-responsive CadC of Escherichia coli.

Tetsch L, Koller C, Dönhöfer A, Jung K.

BMC Microbiol. 2011 Apr 12;11:74. doi: 10.1186/1471-2180-11-74.

45.

Two-point phase correlations of a one-dimensional bosonic Josephson junction.

Betz T, Manz S, Bücker R, Berrada T, Koller Ch, Kazakov G, Mazets IE, Stimming HP, Perrin A, Schumm T, Schmiedmayer J.

Phys Rev Lett. 2011 Jan 14;106(2):020407. Epub 2011 Jan 14.

PMID:
21405210
46.

Crystal structure of the sensory domain of Escherichia coli CadC, a member of the ToxR-like protein family.

Eichinger A, Haneburger I, Koller C, Jung K, Skerra A.

Protein Sci. 2011 Apr;20(4):656-69. doi: 10.1002/pro.594.

47.

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG.

Blood. 2011 Mar 17;117(11):3016-24. doi: 10.1182/blood-2010-08-304683. Epub 2011 Jan 18.

48.

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.

Cortes J, Quintás-Cardama A, Jones D, Ravandi F, Garcia-Manero G, Verstovsek S, Koller C, Hiteshew J, Shan J, O'Brien S, Kantarjian H.

Cancer. 2011 Feb 1;117(3):572-80. doi: 10.1002/cncr.25438. Epub 2010 Sep 30.

49.

Magnetic nanoparticle labeling of astrocytes derived for neural transplantation.

Pickard MR, Jenkins SI, Koller CJ, Furness DN, Chari DM.

Tissue Eng Part C Methods. 2011 Jan;17(1):89-99. doi: 10.1089/ten.TEC.2010.0170. Epub 2010 Sep 28.

PMID:
20666601
50.

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

Greenberg PL, Koller CA, Cabantchik ZI, Warsi G, Glynos T, Paley C, Schiffer C.

Leuk Res. 2010 Dec;34(12):1560-5. doi: 10.1016/j.leukres.2010.06.013. Epub 2010 Jul 8.

PMID:
20615548

Supplemental Content

Loading ...
Support Center